INTRODUCTION
Vitiligo is a common autoimmune inflammatory disease
where there is an absence, deficiency, or dysfunction of melanocytes.1-4 There are many standard therapies for vitiligo, such as psoralen combined with ultraviolet A (PUVA), PUVA Sole5,6 steroids, UVB Narrowband,7 5% tincture iodine solution,
8,9 and lactic acid.10 Response to therapy depends on the severity, location, and time factors of the disease, but it can be divided into 2 groups: the so-called “rapid responders†are patients
who respond quickly to drugs that are prescribed for vitiligo,
and the so-called “nonresponders†are patients who do not respond to prescribed drugs.9
In some cases of vitiligo, such as segmental vitiligo, surgical procedures are recommended for patches resistant to therapy. Autologous melanocyte transplants have been used to treat
vitiligo patches with tissue grafts, such as punch minigrafts,11,12
suction blister epidermal grafting,13 split-thickness grafting,14,15
and cellular grafting, which includes the transplantation of autologous
epidermal cells suspension that comprise non-cultured
melanocyte grafting17-21 and cultured autologous melanocytes.22
The early minigrafting technique is generally associated with numerous problems, including a deficient spread of the grafted melanocytes to the surrounding area and cobblestoning. The other surgical techniques are expensive and require sophisticated
laboratories and personnel.
Therefore, the aim of the present study was to find a new melanocyte-
grafting technique that used micrografts implanted with a needling technique in patients with different types of vitiligo at varying locations on their bodies.
PATIENTS AND METHODS
This interventional case study took place at the Department of
Dermatology and Venereology at Baghdad Teaching Hospital
from December 2010 to September 2011. Twelve patients with
vitiligo were enrolled in this study (5 males and 7 females) and
their ages ranged from 12 to 43 years with a mean ± standard
deviation of 27.53 ± 9.78 years. All clinical types of vitiligo were
treated, including generalized, localized, and segmental vitiligo.
The number of vitiligo patches varied between patients, so the
total number of treated patches was 24 (Table 1).
Inclusion Criteria
Segmental and localized areas of vitiligo were included. In patients
with generalized vitiligo, localized areas were selected and treated because they were cosmetically unacceptable to the patients, requested by the patient, or a test area for further grafting. Each patient’s disease activity was recorded in order to monitor the duration of disease stability, and the patients were divided into 2 groups: (1) stable vitiligo, where there was no disease activity for more than 6 months before grafting and